糖皮质激素联合静脉环磷酰胺治疗特发性肺纤维化急性加重的疗效:倾向评分匹配分析
该回顾性研究纳入102例首次特发性急性加重的IPF患者,采用倾向评分匹配比较糖皮质激素单药与联合静脉环磷酰胺的疗效。匹配后26对患者中,两组90天生存率(84.6% vs 76.9%,P=0.70)、累积生存率(P=0.57)及≥CTCAE 3级不良事件发生率(61.5% vs 65.4%,P=1.00)均无显著差异。
要点
- 联合静脉环磷酰胺较糖皮质激素单药未显著改善AE-IPF患者90天生存率。
- 两组累积生存率及≥CTCAE 3级不良事件发生率均无显著差异。
- AE-IPF optimal治疗仍不明确,联合方案需进一步研究评估。
核心结论
- 倾向评分匹配分析显示,与糖皮质激素单药相比,联合静脉环磷酰胺未显著改善AE-IPF患者急性加重后生存。
研究设计与样本
- 回顾性研究纳入102例连续IPF患者,均为首次特发性急性加重,评估急性加重后生存率与治疗安全性。
- 采用倾向评分匹配分析比较糖皮质激素联合静脉环磷酰胺与糖皮质激素单药的疗效,匹配后形成26对患者。
主要发现
- 整个队列急性加重后90天生存率为64.7%。
- 匹配后糖皮质激素组与联合环磷酰胺组急性加重后90天生存率分别为84.6%与76.9%,差异无统计学意义(P=0.70)。
- 两组累积生存率无显著差异(P=0.57,log-rank检验)。
- 两组≥CTCAE v5.0 3级不良事件发生率分别为61.5%与65.4%,差异无统计学意义(P=1.00)。
临床怎么用
- 对于AE-IPF患者,糖皮质激素联合静脉环磷酰胺较单用糖皮质激素未显示生存获益,临床决策需权衡利弊。
局限性
- 回顾性研究设计,样本量有限(匹配后26对),需进一步研究评估联合治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis (IPF). Although optimal treatment for AE-IPF remains unclear, high-dose corticosteroids (CS) with/without immunosuppressants, including intravenous cyclophosphamide (IVCY), are often used as empirical therapy. However, the survival benefit of adding IVCY to CS therapy is unknown. We investigated the efficacy of this therapy in patients with AE-IPF. METHODS: Overall, 102 consecutive patients with IPF with a first idiopathic AE were included. Post-AE survival rates and treatment safety were retrospectively assessed. Efficacy of CS + IVCY therapy for the first AE was compared with that of CS monotherapy using a propensity score-matched analysis. RESULTS: The post-AE 90-day survival rate of the entire cohort was 64.7%. On the basis of the propensity scores, 26 matched patient pairs were made. Characteristics of matched patients with AE-IPF treated with CS (matched CS group) and those with CS + IVCY (matched CS + IVCY group) were well balanced. No significant between-group differences were observed in post-AE 90-day survival rates (84.6% vs 76.9%; P = 0.70), cumulative survival rates (P = 0.57 by log-rank test) or incidence of adverse events ≥ CTCAE (Common Terminology Criteria for Adverse Events) v5.0 grade 3 (61.5% vs 65.4%; P = 1.00). CONCLUSION: The propensity score-matched analysis demonstrated that compared with CS monotherapy, CS + IVCY therapy did not significantly improve post-AE survival in patients with AE-IPF. Further studies are warranted to assess the efficacy of CS + IVCY therapy for AE-IPF.
引用
- Hozumi H, Hasegawa H, Miyashita K, et al. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis. Respirology. 2019. PMID: 30803100. doi:10.1111/resp.13506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。